Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 18/20 | 0.88 |
| ▸ | FLT1 | P17948 | 4/20 | 0.88 |
| ▸ | PDGFRB | P09619 | 16/20 | 0.70 |
| ▸ | KDR | P35968 | 16/20 | 0.70 |
| ▸ | LCK | P06239 | 3/20 | 0.61 |
| ▸ | FLT3 | P36888 | 2/20 | 0.61 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.61 |
| ▸ | PLK4 | O00444 | 1/20 | 0.61 |
| ▸ | STK25 | O00506 | 1/20 | 0.61 |
| ▸ | CIT | O14578 | 1/20 | 0.61 |
| ▸ | RIOK3 | O14730 | 1/20 | 0.61 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.61 |
| ▸ | GAK | O14976 | 1/20 | 0.61 |
| ▸ | CHUK | O15111 | 1/20 | 0.61 |
| ▸ | MUSK | O15146 | 1/20 | 0.61 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.61 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.61 |
| ▸ | MAP3K13 | O43283 | 1/20 | 0.61 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.61 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3381227 | 0.86 | FGFR1 (0.85) | FGFR1FLT1PDGFRBKDR | |
| SCHEMBL14795331 | 0.84 | FGFR1 (0.86) | FGFR1FLT1PDGFRBKDRLCK | |
| SCHEMBL3841472 | 0.83 | FGFR1 (0.68) | FGFR1FLT1PDGFRBKDRLCK | |
| Dovitinib SCHEMBL30567813 | 0.83 | FGFR1 (0.86) | FGFR1FLT1PDGFRBKDRLCK | |
| SCHEMBL3381338 | 0.83 | FGFR1 (0.86) | FGFR1FLT1PDGFRBKDR | |
| Dovitinib SCHEMBL949705 | 0.83 | FGFR1 (0.86) | FGFR1FLT1PDGFRBKDRLCK | |
| SCHEMBL3379948 | 0.83 | FGFR1 (0.86) | FGFR1FLT1PDGFRBKDRLCK | |
| SCHEMBL3381059 | 0.82 | FGFR1 (1.00) | FGFR1FLT1PDGFRBKDRLCK | |
| Dovitinib SCHEMBL12003201 | 0.82 | FGFR1 (0.85) | FGFR1FLT1PDGFRBKDRLCK | |
| SCHEMBL3840360 | 0.82 | FGFR1 (0.86) | FGFR1FLT1PDGFRBKDRLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2573079-A2 | Benzimidazole quinolinones and uses thereof | Novartis Vaccines and Diagnostics, Inc. (US) | 2013-03-27 | — | — | EP | disclosed |
| EP-1313734-B1 | AZA HETEROCYCLIC DERIVATIVES AND THEIR THERAPEUTIC USE | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2009-11-11 | — | — | EP | disclosed |
| US-7368459-B2 | Heterocyclic compounds | CHIRON CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| US-20070032528-A1 | Heterocyclic compounds | RENHOWE PAUL A | 2007-02-08 | — | — | US | disclosed |
| US-7138409-B2 | Heterocyclic compounds | CHIRON CORPORATION (US) | 2006-11-21 | — | — | US | disclosed |
| US-20050137188-A1 | Heterocyclic compounds | CHIRON CORPORATION | 2005-06-23 | — | — | US | disclosed |
| US-6759417-B2 | VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS; SUCH AS 7-AMINO-6-(1H-BENZIMIDAZOL-2-YL)-3,4-DIHYDRO-5H-IMIDAZO(4,5-B)PYRIDIN-5-ONE | CHIRON CORPORATION | 2004-07-06 | — | — | US | disclosed |
| US-6756383-B2 | SUCH AS 3-(2-(METHOXYCARBONYL)ACETYLAMINO)PYRIDINE-4-CARBOXYLIC ACID FOR TREATMENT OF DISEASES CHARACTERIZED BY ACTIVITY OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYROSINE KINASES; ENZYME INHIBITORS | CHIRON CORPORATION | 2004-06-29 | — | — | US | disclosed |
| US-20040002518-A1 | Heterocyclic compounds | CHIRON CORPORATION | 2004-01-01 | — | — | US | disclosed |
| US-20020103230-A1 | Heterocyclic compounds | CHIRON CORPORATION | 2002-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103230-A1 | Heterocyclic compounds | SLCO2A1, SLCO1B1, SLCO2B1 | FGFR1 1252/4885FLT1 3035/4885PDGFRB 4093/4885 |
| US-20070032528-A1 | Heterocyclic compounds | SLCO4C1, SLCO2B1, SLCO1B1 | FGFR1 560/4885FLT1 2959/4885PDGFRB 2263/4885 |
| US-20050137188-A1 | Heterocyclic compounds | SLCO4C1, SLCO2B1, SLCO1B1 | FGFR1 560/4885FLT1 2959/4885PDGFRB 2263/4885 |
| US-20040002518-A1 | Heterocyclic compounds | SLCO2A1, SLCO1B1, SLCO2B1 | FGFR1 1252/4885FLT1 3035/4885PDGFRB 4093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.